(Q38079790)

28 August 2017

Obstacles to the development of a neuroprotective therapy for Parkinson's disease (English)

1 reference

28 August 2017

1 reference

Fabrizio Stocchi

1

0 references

Charles Warren Olanow

series ordinal

2

object named as

C Warren Olanow

1 reference

PubMed ID

23390094

28 August 2017

language of work or name

English

0 references

publication date

1 January 2013

1 reference

28 August 2017

1 reference

28 August 2017

28

1 reference

28 August 2017

1

1 reference

28 August 2017

3-7

1 reference

Neuroprotection in Parkinson disease: mysteries, myths, and misconceptions

28 August 2017

1 reference

Milestones in PD genetics

21 January 2018

1 reference

Recent advances in the genetics of Parkinson's disease

21 January 2018

1 reference

Leucine-rich repeat kinase 2 (LRRK2) as a potential therapeutic target in Parkinson's disease

21 January 2018

1 reference

Is Parkinson's disease a prion disorder?

21 January 2018

1 reference

Animal models of Parkinson's disease: limits and relevance to neuroprotection studies.

21 January 2018

1 reference

Genetic animal models of Parkinson's disease

21 January 2018

1 reference

The Parkinson Progression Marker Initiative (PPMI).

21 January 2018

1 reference

An introduction to adaptive designs and adaptation in CNS trials

21 January 2018

1 reference

Adaptive designs in clinical drug development: opportunities, challenges, and scope reflections following PhRMA's November 2006 workshop

21 January 2018

1 reference

Ageing and Parkinson's disease: substantia nigra regional selectivity

21 January 2018

1 reference

A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes

21 January 2018

1 reference

Bioactivity of AAV2-neurturin gene therapy (CERE-120): differences between Parkinson's disease and nonhuman primate brains.

21 January 2018

1 reference

The Parkinson's complex: parkinsonism is just the tip of the iceberg

21 January 2018

1 reference

Parkinson's at risk syndrome: can Parkinson's disease be predicted?

21 January 2018

1 reference

Endpoints and analyses to discern disease-modifying drug effects in early Parkinson's disease

21 January 2018

1 reference

A randomized, double-blind, placebo-controlled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson's disease (the ADAGIO study): rationale, design, and baseline characteristics

21 January 2018

1 reference

A double-blind, delayed-start trial of rasagiline in Parkinson's disease

21 January 2018

1 reference

Design innovations and baseline findings in a long-term Parkinson's trial: the National Institute of Neurological Disorders and Stroke Exploratory Trials in Parkinson's Disease Long-Term Study-1.

21 January 2018

1 reference

Defining disease-modifying therapies for PD--a road map for moving forward

21 January 2018

1 reference

Overcoming obstacles in Parkinson's disease

21 January 2018

1 reference

Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Scale presentation and clinimetric testing results

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/MDS.25337

1 reference

28 August 2017

1 reference

PubMed ID

23390094